Ultragenyx Pharmaceutical (RARE) EBIAT: 2016-2025
Historic EBIAT for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$180.4 million.
- Ultragenyx Pharmaceutical's EBIAT fell 35.12% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$579.8 million, marking a year-over-year decrease of 3.73%. This contributed to the annual value of -$569.2 million for FY2024, which is 6.17% up from last year.
- As of Q3 2025, Ultragenyx Pharmaceutical's EBIAT stood at -$180.4 million, which was down 56.95% from -$115.0 million recorded in Q2 2025.
- Over the past 5 years, Ultragenyx Pharmaceutical's EBIAT peaked at -$73.0 million during Q3 2021, and registered a low of -$245.1 million during Q3 2022.
- Over the past 3 years, Ultragenyx Pharmaceutical's median EBIAT value was -$151.1 million (recorded in 2025), while the average stood at -$147.5 million.
- Per our database at Business Quant, Ultragenyx Pharmaceutical's EBIAT tumbled by 583.62% in 2021 and then surged by 34.87% in 2023.
- Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's EBIAT stood at -$122.5 million in 2021, then fell by 23.99% to -$151.8 million in 2022, then grew by 18.86% to -$123.2 million in 2023, then decreased by 8.28% to -$133.4 million in 2024, then crashed by 35.12% to -$180.4 million in 2025.
- Its EBIAT stands at -$180.4 million for Q3 2025, versus -$115.0 million for Q2 2025 and -$151.1 million for Q1 2025.